EuroFlow™ Databases for Plasma cell dyscrasias

The number of immunophenotypical markers that can be evaluated in 8-color assays and the high number of cells acquired in MM MRD assessment increase the complexity of data analysis. EuroFlow™ developed and validated a database containing representative flow cytometry data sets from normal bone marrow samples processed in different standardized centers. The database (available through Infinicyt™), when used with files that follow standardized operating procedures, allows for an automated analysis of the complete bone marrow sample.

How was the reference database built?

EuroFlow™ collected normal bone marrow samples stained with the MM MRD panel following EuroFlow™ SOPs. The samples were collected in different centers to reflect biological and technical variability regarding different laboratories, instruments and operators.

EuroFlow™ experts analyzed those normal samples and created a library of reference populations. When comparing a new sample with this database, all populations of the sample will be automatically identified.

How to compare a new case with EuroFlow™ MM MRD Database using Infinicyt™ Automated Gating & Identification tool?

  1. Compatible FCS file
    Acquired using the EuroFlow™ SOPs for instrument set-up, sample preparation and antibody panel.
  2. Clustering
    All events are automatically identified by clustering algorithms.
  3. Identification with EuroFlow Databases
    Infinicyt™ automatically compares the clusters with EuroFlow™ Database:
    – Clusters identical to cell populations included in the database are directly renamed with the name of those populations.
    – Clusters that are not identical to the ones included in the database are assigned to Check Populations. The user has to review them and decide whether they are normal or abnormal.
  4. Automatic Report includes (click here to see an example)
    – Frequency of each population with reference ranges.
    – Clinically relevant comments and conclusions.
    – Available in different languages.

Resources

Publications:

  1. Flores-Montero, et al. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma. Cytometry B Clin Cytom. 2016 Jan;90(1):61-72. Go to publication.
  2. Sanoja-Flores L, et al. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood. 2019 Oct; 8(12):epub. Go to publication.
  3. Flores-Montero J, et al. Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017 Oct;31(10):2094-103. Go to publication.
  4. Sanoja-Flores L, et al. Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC). Blood Cancer J. 2018 Nov;8(12):117. Go to publication.
  5. Sanoja-Flores L, et al. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy. Blood. 2019 Oct; 8(12):epub. Go to publication.